338 related articles for article (PubMed ID: 30783971)
1. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
Yu W; Wu Z
Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
[TBL] [Abstract][Full Text] [Related]
2. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
3. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
[TBL] [Abstract][Full Text] [Related]
4. Somatic Gene Editing of
McCullough KT; Boye SL; Fajardo D; Calabro K; Peterson JJ; Strang CE; Chakraborty D; Gloskowski S; Haskett S; Samuelsson S; Jiang H; Witherspoon CD; Gamlin PD; Maeder ML; Boye SE
Hum Gene Ther; 2019 May; 30(5):571-589. PubMed ID: 30358434
[TBL] [Abstract][Full Text] [Related]
5. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
6. CRISPR Systems Suitable for Single AAV Vector Delivery.
Stevanovic M; Piotter E; McClements ME; MacLaren RE
Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
[TBL] [Abstract][Full Text] [Related]
7. Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency.
Fry LE; Peddle CF; Stevanovic M; Barnard AR; McClements ME; MacLaren RE
CRISPR J; 2020 Aug; 3(4):276-283. PubMed ID: 32833533
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases.
Rasoulinejad SA; Maroufi F
Mol Biotechnol; 2021 Sep; 63(9):768-779. PubMed ID: 34057656
[TBL] [Abstract][Full Text] [Related]
9. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.
Moreno AM; Fu X; Zhu J; Katrekar D; Shih YV; Marlett J; Cabotaje J; Tat J; Naughton J; Lisowski L; Varghese S; Zhang K; Mali P
Mol Ther; 2018 Jul; 26(7):1818-1827. PubMed ID: 29754775
[TBL] [Abstract][Full Text] [Related]
10. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
[TBL] [Abstract][Full Text] [Related]
11. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
12. Rapid and Simple Screening of CRISPR Guide RNAs (gRNAs) in Cultured Cells Using Adeno-Associated Viral (AAV) Vectors.
Fakhiri J; Nickl M; Grimm D
Methods Mol Biol; 2019; 1961():111-126. PubMed ID: 30912043
[TBL] [Abstract][Full Text] [Related]
13. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
14. Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing.
Gu X; Wang D; Xu Z; Wang J; Guo L; Chai R; Li G; Shu Y; Li H
Genome Biol; 2021 Mar; 22(1):86. PubMed ID: 33752742
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
16. Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.
Li F; Hung SSC; Mohd Khalid MKN; Wang JH; Chrysostomou V; Wong VHY; Singh V; Wing K; Tu L; Bender JA; Pébay A; King AE; Cook AL; Wong RCB; Bui BV; Hewitt AW; Liu GS
Hum Gene Ther; 2019 Nov; 30(11):1349-1360. PubMed ID: 31373227
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
[TBL] [Abstract][Full Text] [Related]
18. Design and Assembly of CRISPR/Cas9 Lentiviral and rAAV Vectors for Targeted Genome Editing.
Sandoval IM; Collier TJ; Manfredsson FP
Methods Mol Biol; 2019; 1937():29-45. PubMed ID: 30706388
[TBL] [Abstract][Full Text] [Related]
19. High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.
Gwiazda KS; Grier AE; Sahni J; Burleigh SM; Martin U; Yang JG; Popp NA; Krutein MC; Khan IF; Jacoby K; Jensen MC; Rawlings DJ; Scharenberg AM
Mol Ther; 2016 Sep; 24(9):1570-80. PubMed ID: 27203437
[TBL] [Abstract][Full Text] [Related]
20. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.
Edraki A; Mir A; Ibraheim R; Gainetdinov I; Yoon Y; Song CQ; Cao Y; Gallant J; Xue W; Rivera-Pérez JA; Sontheimer EJ
Mol Cell; 2019 Feb; 73(4):714-726.e4. PubMed ID: 30581144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
